Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Allurion Technologies Inc (ALUR)

Allurion Technologies Inc (ALUR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,746
  • Shares Outstanding, K 9,263
  • Annual Sales, $ 32,110 K
  • Annual Income, $ -26,150 K
  • EBIT $ -41 M
  • EBITDA $ -40 M
  • 60-Month Beta -0.45
  • Price/Sales 0.49
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -7.00
  • Growth Rate Est. (year over year) +14,371.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0200 +66.67%
on 11/25/25
1.8500 -8.11%
on 11/11/25
+0.0050 (+0.29%)
since 11/05/25
3-Month
1.0200 +66.67%
on 11/25/25
2.3000 -26.09%
on 09/23/25
-0.5300 (-23.77%)
since 09/05/25
52-Week
1.0200 +66.67%
on 11/25/25
16.8100 -89.89%
on 01/24/25
-7.3900 (-81.30%)
since 12/05/24

Most Recent Stories

More News
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

Average Total Weight Loss of 23% With 14% Increase in Lean Body Mass After 12 Months All patients remained adherent to tirzepatide for the duration of the study

ALUR : 1.7000 (-0.58%)
New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

Case-controlled study in 1,143 patients demonstrates superior weight reduction, fat mass loss, and visceral fat loss with the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle...

ALUR : 1.7000 (-0.58%)
Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with ProSurg Medical, a leading Brazilian medical device company...

ALUR : 1.7000 (-0.58%)
Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update. ...

ALUR : 1.7000 (-0.58%)
Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

Passing of key audits with zero findings and completion of Day-100 meeting are significant milestones in the FDA PMA process as the Company enters final stages of FDA review process for its Allurion Smart...

ALUR : 1.7000 (-0.58%)
Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the third quarter...

ALUR : 1.7000 (-0.58%)
Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss

Multicenter study across six countries demonstrates safety and efficacy of two consecutive treatments in adults with obesity Weight loss of greater than 20% on par with...

ALUR : 1.7000 (-0.58%)
Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its participation in the ROTH 4 th Annual Healthcare Opportunities Conference, which...

ALUR : 1.7000 (-0.58%)
Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update. ...

ALUR : 1.7000 (-0.58%)
Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the second quarter...

ALUR : 1.7000 (-0.58%)

Business Summary

Allurion Technologies Inc. is dedicated to ending obesity. The Allurion Program is a weight loss platform which combines the Allurion Gastric Balloon and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers,...

See More

Key Turning Points

3rd Resistance Point 1.8900
2nd Resistance Point 1.8200
1st Resistance Point 1.7600
Last Price 1.7000
1st Support Level 1.6300
2nd Support Level 1.5600
3rd Support Level 1.5000

See More

52-Week High 16.8100
Fibonacci 61.8% 10.7782
Fibonacci 50% 8.9150
Fibonacci 38.2% 7.0518
Last Price 1.7000
52-Week Low 1.0200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar